Search results
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 22 hours agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Sarepta Therapeutics gains as Pfizer failure removes overhang By Investing.com
Investing.com· 48 minutes agoSarepta Therapeutics (NASDAQ:SRPT) stock rose over 3% Thursday after Pfizer (NYSE:PFE) announced...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 3 hours agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 23 hours agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 2 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 3 hours agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 5 hours agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Bridgeway Capital Management LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 5 hours agoBridgeway Capital Management LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 26.0% during the 4th quarter, according to its most recent 13F filing ...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 1 day agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 22 hours agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after ...